淋巴瘤化疗导致的乙型肝炎病毒再激活及其预防  

Prevention of Lymphadenoma Chemotherapy-related HBV Reactivation

作　　者：冯洪玲[1] 曹武奎[1] 

机构地区：[1]天津传染病医院重症肝炎科,天津300192

出　　处：《医学综述》2009年第21期3256-3260,共5页Medical Recapitulate

摘　　要：淋巴瘤化疗相关乙型肝炎病毒(HBV)再激活的发生率及病死率均有逐年上升趋势,因此预防化疗所致的HBV再激活尤为重要。发生HBV再激活的危险性与HBV的感染、抗肿瘤药物的应用等有关。对于合并HBV慢性感染的淋巴瘤患者,化疗前应施行预防性抗病毒治疗,从而避免HBV再激活,以完成多疗程化疗,延长生命,提高生活质量。化疗前预防性抗HBV治疗得到普遍认同,本文就这一领域的研究予以综述。In recent years,the incidence rate and mortality of lymphadenoma chemotherapy-related HBV reactivation has an ascendant tendency,thus,the prevention of chemotherapy-related HBV reactivation seems to be very important.Several studies showed that risk factors associated with HBV reactivation include hepatitis B virus（HBV）and antineoplastic agents.For the lymphoma patients with chronic HBV infection,prophylactic antiviral therapy before chemotherapy is needed,in order to avoid the re-activation of HBV,complete the multi-course chemotherapy,prolong life,and improve the quality of life.This article reviewed the progress in this field.

关 键 词：淋巴瘤 乙型肝炎病毒 乙型肝炎病毒再激活 化疗 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]